branebrutinib + abatacept + branebrutinib placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune Disorder
Conditions
Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
Trial Timeline
Jan 7, 2020 → Dec 5, 2022
NCT ID
NCT04186871About branebrutinib + abatacept + branebrutinib placebo
branebrutinib + abatacept + branebrutinib placebo is a phase 2 stage product being developed by Bristol Myers Squibb for Autoimmune Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04186871. Target conditions include Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus.
What happened to similar drugs?
0 of 13 similar drugs in Autoimmune Disorder were approved
Approved (0) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04186871 | Phase 2 | Completed |
Competing Products
20 competing products in Autoimmune Disorder